Published in Vaccine Weekly, November 10th, 1997
The announcement follows the company's earlier meeting with officials from the Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration (FDA). Following this meeting to discuss the proposed Phase III clinical trial, the company has moved...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.